- Home
- GLBZ vs CGTX Comparison
GLBZ vs CGTX Comparison
Compare GLBZ & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- CGTX
- Stock Information
- Founded
- GLBZ 1949
- CGTX 2007
- Country
- GLBZ United States
- CGTX United States
- Employees
- GLBZ N/A
- CGTX N/A
- Industry
- GLBZ Major Banks
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- CGTX Health Care
- Exchange
- GLBZ Nasdaq
- CGTX Nasdaq
- Market Cap
- GLBZ 17.3M
- CGTX 16.1M
- IPO Year
- GLBZ N/A
- CGTX 2021
- Fundamental
- Price
- GLBZ $5.84
- CGTX $0.64
- Analyst Decision
- GLBZ
- CGTX Buy
- Analyst Count
- GLBZ 0
- CGTX 6
- Target Price
- GLBZ N/A
- CGTX $8.00
- AVG Volume (30 Days)
- GLBZ 7.5K
- CGTX 3.6M
- Earning Date
- GLBZ 10-31-2024
- CGTX 11-13-2024
- Dividend Yield
- GLBZ 5.08%
- CGTX N/A
- EPS Growth
- GLBZ N/A
- CGTX N/A
- EPS
- GLBZ 0.03
- CGTX N/A
- Revenue
- GLBZ $11,317,000.00
- CGTX N/A
- Revenue This Year
- GLBZ N/A
- CGTX N/A
- Revenue Next Year
- GLBZ N/A
- CGTX N/A
- P/E Ratio
- GLBZ $179.48
- CGTX N/A
- Revenue Growth
- GLBZ N/A
- CGTX N/A
- 52 Week Low
- GLBZ $3.37
- CGTX $0.34
- 52 Week High
- GLBZ $7.16
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- GLBZ 51.20
- CGTX 82.86
- Support Level
- GLBZ $5.81
- CGTX $0.43
- Resistance Level
- GLBZ $6.99
- CGTX $0.52
- Average True Range (ATR)
- GLBZ 0.21
- CGTX 0.06
- MACD
- GLBZ -0.03
- CGTX 0.04
- Stochastic Oscillator
- GLBZ 16.10
- CGTX 67.21
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.